cnta-20210630
FALSE2021Q20001847903December 3100018479032021-01-012021-06-300001847903us-gaap:CommonStockMember2021-01-012021-06-300001847903cnta:AmericanDepositarySharesMember2021-01-012021-06-30xbrli:shares00018479032021-08-13iso4217:USD00018479032021-06-3000018479032020-12-31iso4217:GBPxbrli:shares00018479032021-04-012021-06-3000018479032021-01-302021-06-3000018479032021-01-012021-01-2900018479032020-04-012020-06-3000018479032020-01-012020-06-30iso4217:USDxbrli:shares0001847903us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMembercnta:CentessaPharmaceuticalsPlcMember2020-12-310001847903us-gaap:CommonStockMembercnta:CentessaPharmaceuticalsPlcMember2020-12-310001847903us-gaap:AdditionalPaidInCapitalMembercnta:CentessaPharmaceuticalsPlcMember2020-12-310001847903cnta:CentessaPharmaceuticalsPlcMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001847903us-gaap:RetainedEarningsMembercnta:CentessaPharmaceuticalsPlcMember2020-12-310001847903cnta:CentessaPharmaceuticalsPlcMember2020-12-310001847903cnta:CentessaPharmaceuticalsPlcMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-01-290001847903cnta:CentessaPharmaceuticalsPlcMember2021-01-012021-01-290001847903us-gaap:RetainedEarningsMembercnta:CentessaPharmaceuticalsPlcMember2021-01-012021-01-290001847903us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMembercnta:CentessaPharmaceuticalsPlcMember2021-01-290001847903us-gaap:CommonStockMembercnta:CentessaPharmaceuticalsPlcMember2021-01-290001847903us-gaap:AdditionalPaidInCapitalMembercnta:CentessaPharmaceuticalsPlcMember2021-01-290001847903cnta:CentessaPharmaceuticalsPlcMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-290001847903us-gaap:RetainedEarningsMembercnta:CentessaPharmaceuticalsPlcMember2021-01-290001847903cnta:CentessaPharmaceuticalsPlcMember2021-01-290001847903us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2021-01-290001847903us-gaap:CommonStockMember2021-01-290001847903us-gaap:AdditionalPaidInCapitalMember2021-01-290001847903us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-290001847903us-gaap:RetainedEarningsMember2021-01-2900018479032021-01-2900018479032021-01-302021-03-310001847903us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2021-01-302021-03-310001847903us-gaap:CommonStockMember2021-01-302021-03-310001847903us-gaap:AdditionalPaidInCapitalMember2021-01-302021-03-310001847903us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-302021-03-310001847903us-gaap:RetainedEarningsMember2021-01-302021-03-310001847903us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2021-03-310001847903us-gaap:CommonStockMember2021-03-310001847903us-gaap:AdditionalPaidInCapitalMember2021-03-310001847903us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001847903us-gaap:RetainedEarningsMember2021-03-3100018479032021-03-310001847903us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2021-04-012021-06-300001847903us-gaap:CommonStockMember2021-04-012021-06-300001847903us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001847903us-gaap:CommonStockMemberus-gaap:IPOMember2021-04-012021-06-300001847903us-gaap:IPOMemberus-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001847903us-gaap:IPOMember2021-04-012021-06-300001847903us-gaap:CommonStockMemberus-gaap:OverAllotmentOptionMember2021-04-012021-06-300001847903us-gaap:AdditionalPaidInCapitalMemberus-gaap:OverAllotmentOptionMember2021-04-012021-06-300001847903us-gaap:OverAllotmentOptionMember2021-04-012021-06-300001847903us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001847903us-gaap:RetainedEarningsMember2021-04-012021-06-300001847903us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2021-06-300001847903us-gaap:CommonStockMember2021-06-300001847903us-gaap:AdditionalPaidInCapitalMember2021-06-300001847903us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001847903us-gaap:RetainedEarningsMember2021-06-300001847903us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2020-12-310001847903us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2020-12-310001847903cnta:SeriesSeedPreferredStockMemberus-gaap:PreferredStockMember2020-12-310001847903us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2021-01-290001847903cnta:SeriesSeedPreferredStockMemberus-gaap:PreferredStockMember2021-01-290001847903us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2019-12-310001847903us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2019-12-310001847903cnta:SeriesSeedPreferredStockMemberus-gaap:PreferredStockMember2019-12-3100018479032019-12-3100018479032020-01-012020-03-310001847903us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2020-03-310001847903us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2020-03-310001847903cnta:SeriesSeedPreferredStockMemberus-gaap:PreferredStockMember2020-03-3100018479032020-03-310001847903us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2020-06-300001847903us-gaap:PreferredStockMemberus-gaap:SeriesBPreferredStockMember2020-06-300001847903cnta:SeriesSeedPreferredStockMemberus-gaap:PreferredStockMember2020-06-3000018479032020-06-3000018479032021-01-312021-06-3000018479032021-01-300001847903us-gaap:IPOMember2021-06-012021-06-300001847903us-gaap:IPOMember2021-06-300001847903us-gaap:OverAllotmentOptionMember2021-06-012021-06-300001847903us-gaap:OverAllotmentOptionMember2021-06-3000018479032021-06-012021-06-30cnta:segment0001847903us-gaap:CommonStockMember2021-01-302021-06-300001847903us-gaap:EmployeeStockOptionMember2021-01-302021-06-30xbrli:pure0001847903cnta:CentessaSubsidiariesMember2021-01-290001847903cnta:CentessaSubsidiariesMember2021-01-292021-01-290001847903cnta:CentessaSubsidiariesMember2021-01-012021-01-290001847903cnta:CentessaSubsidiariesMember2021-06-300001847903cnta:CentessaSubsidiariesMember2021-01-302021-06-300001847903us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001847903us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001847903us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001847903us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001847903us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001847903us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001847903us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2020-12-310001847903us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2021-01-012021-01-290001847903us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2021-01-290001847903cnta:ContingentValueRightsMember2021-01-290001847903cnta:ContingentValueRightsMember2021-01-302021-03-310001847903cnta:ContingentValueRightsMember2021-03-310001847903cnta:ContingentValueRightsMember2021-04-012021-06-300001847903cnta:ContingentValueRightsMember2021-06-300001847903cnta:MorphogenLXMember2020-12-310001847903cnta:ZFactorMember2020-12-310001847903cnta:LockBodyMember2020-12-310001847903cnta:UnsecuredConvertibleTermNotesDueJune2021Memberus-gaap:ConvertibleNotesPayableMember2020-12-3100018479032020-12-012020-12-310001847903us-gaap:PreferredStockMemberus-gaap:SeriesAPreferredStockMember2021-01-292021-01-29iso4217:GBP0001847903cnta:ConvertibleTermNotesDueAugust2021Memberus-gaap:ConvertibleNotesPayableMember2019-07-310001847903cnta:ConvertibleTermNotesDueAugust2021Member2019-07-012019-07-310001847903cnta:ConvertibleTermNotesDueAugust2021Member2020-11-012020-11-300001847903cnta:CentessaSubsidiariesMemberus-gaap:CommonStockMember2021-01-292021-01-290001847903cnta:CentessaSubsidiariesMembercnta:ReplacementEquityAwardsMember2021-01-292021-01-2900018479032021-01-292021-01-290001847903us-gaap:ResearchAndDevelopmentExpenseMember2021-04-012021-06-300001847903us-gaap:ResearchAndDevelopmentExpenseMember2021-01-302021-06-300001847903us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-01-290001847903us-gaap:ResearchAndDevelopmentExpenseMember2020-04-012020-06-300001847903us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-06-300001847903us-gaap:GeneralAndAdministrativeExpenseMember2021-04-012021-06-300001847903us-gaap:GeneralAndAdministrativeExpenseMember2021-01-302021-06-300001847903us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-01-290001847903us-gaap:GeneralAndAdministrativeExpenseMember2020-04-012020-06-300001847903us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-06-3000018479032021-05-310001847903us-gaap:EmployeeStockOptionMember2021-01-012021-06-300001847903us-gaap:EmployeeStockOptionMember2021-01-302021-06-300001847903us-gaap:EmployeeStockOptionMember2021-06-300001847903us-gaap:RestrictedStockMember2021-01-292021-01-290001847903us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2021-04-012021-06-300001847903us-gaap:RestrictedStockMember2021-01-290001847903us-gaap:RestrictedStockMember2021-01-302021-06-300001847903us-gaap:RestrictedStockMember2021-06-300001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:ZFactorMember2015-12-31iso4217:USDiso4217:GBP00018479032015-12-310001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:ZFactorMember2021-04-012021-06-300001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:ZFactorMember2021-01-012021-01-290001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:ZFactorMember2020-04-012020-06-300001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:ZFactorMember2021-01-302021-06-300001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:MorphogenLXMember2015-12-310001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:MorphogenLXMember2021-01-012021-01-290001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-04-012021-06-300001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-01-302021-06-300001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2020-04-012020-06-300001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:PalladioMember2021-06-300001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:PalladioMembercnta:PfizerMember2021-06-300001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:PalladioMember2021-01-302021-06-300001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:CambridgeEnterpriseLimitedMembercnta:ApcinteXMember2021-06-300001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:ApcinteXMember2021-01-302021-06-300001847903cnta:PegaOneMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:HoffmanLaRocheLtdMember2021-06-300001847903cnta:PegaOneMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:HoffmanLaRocheLtdMember2021-01-012021-06-300001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:JanpixLimitedMember2021-06-300001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:CapellaBiosciencesLimitedMembercnta:LonzaSalesAGMember2021-06-300001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:CapellaBiosciencesLimitedMembercnta:LonzaSalesAGMember2021-04-012021-06-300001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:CapellaBiosciencesLimitedMembercnta:LonzaSalesAGMember2021-01-302021-06-300001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:PearlRiverBioGmbHMembercnta:LeadDiscoveryCenterGmbHMembercnta:PearlRiverBioGmbHLicenseAgreementWithLeaseDiscoveryCenterGmbHForExon20Member2019-03-3100018479032019-03-310001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:PearlRiverBioGmbHMembercnta:LeadDiscoveryCenterGmbHMembercnta:PearlRiverBioGmbHLicenseAgreementWithLeadDiscoveryCenterGmbHForC797Member2019-03-310001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:XChemIncMembercnta:OrexiaTherapeuticsMember2021-06-300001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:HeptaresTherapeuticsLimitedMembercnta:OrexiaTherapeuticsMember2019-01-3100018479032019-01-310001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:InexiaLimitedMembercnta:HeptaresTherapeuticsLimitedMember2019-01-310001847903us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembercnta:OptiNoseASMembercnta:InexiaLimitedMember2021-06-300001847903cnta:BankOfEnglandOfficialRateMembercnta:CentessaPredecessorGroupMembercnta:TermLoanWithUltrahumanMembersrt:AffiliatedEntityMember2021-01-012021-06-300001847903cnta:CentessaPredecessorGroupMembercnta:TermLoanWithUltrahumanMembersrt:AffiliatedEntityMember2021-01-012021-06-300001847903srt:AffiliatedEntityMember2020-04-012020-06-300001847903srt:AffiliatedEntityMember2020-01-012020-06-300001847903srt:AffiliatedEntityMember2021-01-012021-01-290001847903srt:AffiliatedEntityMember2021-04-012021-06-300001847903srt:AffiliatedEntityMember2021-01-302021-06-300001847903cnta:SupportServiceAgreementWithUltrahumanServicesMembersrt:AffiliatedEntityMember2020-04-012020-06-300001847903cnta:SupportServiceAgreementWithUltrahumanServicesMembersrt:AffiliatedEntityMember2020-01-012020-06-300001847903cnta:SupportServiceAgreementWithUltrahumanServicesMembersrt:AffiliatedEntityMember2021-01-012021-01-290001847903cnta:MasterServicesAgreementsWithTheCambridgePartnershipLimitedMembersrt:AffiliatedEntityMember2020-04-012020-06-300001847903cnta:MasterServicesAgreementsWithTheCambridgePartnershipLimitedMembersrt:AffiliatedEntityMember2020-01-012020-06-300001847903cnta:MasterServicesAgreementsWithTheCambridgePartnershipLimitedMembersrt:AffiliatedEntityMember2021-01-012021-01-290001847903cnta:MasterServicesAgreementsWithTheFoundryCambridgeLimitedMembersrt:AffiliatedEntityMember2020-04-012020-06-300001847903cnta:MasterServicesAgreementsWithTheFoundryCambridgeLimitedMembersrt:AffiliatedEntityMember2020-01-012020-06-300001847903cnta:MasterServicesAgreementsWithTheFoundryCambridgeLimitedMembersrt:AffiliatedEntityMember2021-01-012021-01-290001847903srt:AffiliatedEntityMembercnta:MasterServicesAgreementsWithRxCelerateLimitedMember2020-04-012020-06-300001847903srt:AffiliatedEntityMembercnta:MasterServicesAgreementsWithRxCelerateLimitedMember2020-01-012020-06-300001847903srt:AffiliatedEntityMembercnta:MasterServicesAgreementsWithRxCelerateLimitedMember2021-01-012021-01-290001847903srt:AffiliatedEntityMembercnta:MasterServicesAgreementsWithRxBiologicsLimitedMember2020-04-012020-06-300001847903srt:AffiliatedEntityMembercnta:MasterServicesAgreementsWithRxBiologicsLimitedMember2020-01-012020-06-300001847903srt:AffiliatedEntityMembercnta:MasterServicesAgreementsWithRxBiologicsLimitedMember2021-01-012021-01-290001847903srt:AffiliatedEntityMembercnta:MasterServicesAgreementsWithCambridgeProteinWorksMember2020-04-012020-06-300001847903srt:AffiliatedEntityMembercnta:MasterServicesAgreementsWithCambridgeProteinWorksMember2020-01-012020-06-300001847903srt:AffiliatedEntityMembercnta:MasterServicesAgreementsWithCambridgeProteinWorksMember2021-01-012021-01-290001847903srt:AffiliatedEntityMembercnta:MasterServicesAgreementsWithCambridgeProteinWorksMember2021-04-012021-06-300001847903srt:AffiliatedEntityMembercnta:MasterServicesAgreementsWithCambridgeProteinWorksMember2021-01-302021-06-300001847903us-gaap:InvestorMember2021-01-302021-06-30
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2021
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from   to
Commission file number 001-04321
CENTESSA PHARMACEUTICALS PLC
(Exact name of registrant as specified in its charter)
England and WalesNot applicable
(State or other jurisdiction of
 incorporation or organization)
(I.R.S. Employer Identification No.)
3rd Floor
1 Ashley Road
Altrincham
Cheshire WA14 2DT
United Kingdom
(Address of principal executive offices and zip code)

+44 7391 789784
Registrant's telephone number, including area code
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Ordinary shares, nominal value £0.002 per share
CNTA
Nasdaq Stock Market, LLC*
American Depositary Shares, each representing one ordinary share, nominal value £0.002 per share
CNTANasdaq Stock Market, LLC
*Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market, LLC.
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.    Yes  o    No  x
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     Yes  x   No  o 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Large accelerated filer
o
Accelerated filer
o
Non-accelerated filer  
x
Smaller reporting company
o
Emerging growth company
x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).     Yes   o     No  x

The registrant had outstanding 89,899,419 ordinary shares as of August 13, 2021.




Table of Contents
Summary of the Material Risks Associated with Our Business

Our business is subject to numerous risks and uncertainties that you should be aware of in evaluating our business. These risks are described more fully in ‘Item 1A - Risk Factors,’ and include, but are not limited to, the following:

We may not be successful in our efforts to use our differentiated asset-centric business model to build a pipeline of product candidates with commercial value.
A single or limited number of subsidiaries may comprise a large proportion of our value.
We face challenges, risks and expenses related to the integration of the operations of our asset-centric Centessa Subsidiaries, as well as the management of the expected growth in the scale and complexity of our operations.
We, and our subsidiaries have incurred net losses since inception, and we expect to continue to incur losses for the foreseeable future and may never achieve or maintain profitability.
We will need substantial additional funds to advance development of our product candidates, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or future product candidates.
Our product candidates are in various stages of development, including many in preclinical stages, and may fail in development or suffer delays that materially adversely affect their commercial viability.
We may not be successful in our efforts to identify, discover, in-license or otherwise acquire additional product candidates and may fail to capitalize on programs or product candidates that may represent a greater commercial opportunity or for which there is a greater likelihood of success.
Success in preclinical studies or early clinical trials may not be indicative of results obtained in later trials.
We may encounter substantial delays or challenges in the initiation, conduct or completion of our clinical trials, and the results of clinical development are uncertain.
Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of our product candidates.
We may be unable to obtain U.S. or foreign regulatory approval and, as a result, unable to commercialize our product candidates.
We rely, and expect to continue to rely, on third parties to conduct our preclinical studies and clinical trials and if these third parties perform in an unsatisfactory manner, our business could be substantially harmed.
We could experience manufacturing problems that result in delays in our development or commercialization of our programs or otherwise harm our business.
If we are unable to obtain and maintain sufficient patent and other intellectual property protection for our product candidates and technology or other product candidates that may be identified, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize product candidates similar or identical to the product candidates, and our ability to successfully commercialize the product candidates and other product candidates that we may pursue may be impaired.


2

Table of Contents
Summary of the Material Risks Associated with Our Business (continued)

The patent protection we obtain for our product candidates and technology may be challenged or not sufficient enough to provide us with any competitive advantage.
A number of our programs and associated product candidates are heavily dependent on licensed intellectual property. If we were to lose our rights to licensed intellectual property, we may not be able to continue developing or commercializing our product candidates, if approved. If we breach any of the agreements under which we license the use, development and commercialization rights to our product candidates or technology from third parties or, in certain cases, we fail to meet certain development deadlines, we could lose license rights that are important to our business.
We have never commercialized a product candidate and we may lack the necessary expertise, personnel and resources to successfully commercialize any of our products that receive regulatory approval on our own or together with collaborators.
Our international operations may expose us to business, regulatory, legal, political, operational, financial, pricing and reimbursement risks associated with doing business across multiple jurisdictions outside of the United States.
We are an emerging growth company and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our ADSs less attractive to investors.
• We have material weaknesses in our internal control systems over financial reporting and will need to hire additional personnel and design and implement proper and effective internal controls over financial reporting. We may identify additional material weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements in our financial statements. If we fail to remediate our material weaknesses, we may not be able to report our financial results accurately or to prevent fraud.
If we fail to develop or maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired.
Holders of ADSs may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares.
There is substantial uncertainty as to whether we are or will be a “passive foreign investment company” (“PFIC”). If we are a PFIC, there could be material adverse U.S. federal income tax consequences to U.S. holders.

3

Table of Contents
TABLE OF CONTENTS
Page
Item 6.


SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, or 10-Q, contains express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties. In some cases, forward-looking statements may be identified by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements and opinions contained in this 10-Q are based upon information available to our management as of the date of this 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Forward-looking statements contained in this 10-Q include, but are not limited to, statements about:
the initiation, timing, progress and results (preliminary, interim or final) of our preclinical studies and clinical trials, and our research and development programs;
our ability to advance our product candidates into, and successfully complete, clinical trials;
our reliance on the success of our product candidates and our pipeline programs;
our ability to utilize our screening platform to identify and advance additional product candidates into clinical development;
our ability to become the partner of choice to attract founder-subject matter experts with high conviction programs;
the timing or likelihood of regulatory filings and approvals;
the impact of the ongoing COVID-19 pandemic on our business and operations;
the commercialization of our product candidates, if approved;
our ability to develop sales and marketing capabilities;
4

Table of Contents
the pricing, coverage and reimbursement of our product candidates, if approved;
the implementation of our business model, strategic plans for our business, product candidates and technology;
the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;
our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties;
cost associated prosecuting and maintaining our intellectual property and with defending intellectual property infringement, product liability and other claims;
legal and regulatory development in the United States, the European Union, the United Kingdom and other jurisdictions;
estimates of our expenses, future revenues, capital requirements and our needs for additional financing;
the potential benefits of strategic collaboration agreements and our ability to negotiate and enter into strategic arrangements;
our ability to identify collaboration opportunities and to establish and maintain collaborations;
our ability to obtain additional funding;
the rate and degree of market acceptance of any approved products;
developments relating to our competitors and our industry, including competing therapies and our ability to respond to such developments;
our ability to effectively manage our anticipated growth;
our ability to attract and retain qualified employees and key personnel;
our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act;
statements regarding future revenue, hiring plans, expenses, capital expenditures, capital requirements and share performance;
our expected use of proceeds of our IPO;
the future trading price of the ADSs and impact of securities analysts’ reports on these prices; and
other risks and uncertainties, including those listed under the caption “Risk Factors.”

You should refer to the section titled “Item 1A. Risk Factors” in this 10-Q for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot be assured that the forward-looking statements in this 10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, these statements should not be regarded as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

You should read this 10-Q and the documents that we reference in this 10-Q and have filed as exhibits to this 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.
5

Table of Contents
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Centessa Pharmaceuticals plc (Successor) and Centessa Predecessor Group (Predecessor)
Consolidated and Combined Balance Sheets
(unaudited)
(amounts in thousands except share and per share data)
SuccessorPredecessor
June 30, 2021December 31, 2020
Assets
Current assets:
Cash and cash equivalents$613,759 $7,227 
Tax incentive receivable13,939 2,633 
Prepaid expenses and other current assets15,984 1,305 
Total current assets
643,682 11,165 
Property and equipment, net75  
Tax incentive receivable 552 
Total assets
$643,757 $11,717 
Liabilities, convertible preferred shares, combined deficit and shareholders’ equity
Current liabilities:
Accounts payable$7,261 $1,032 
Accrued expenses and other current liabilities16,924 1,047 
Convertible term notes 5,339 
Term loans 288 
Derivative liability 913 
Total current liabilities24,185 8,619 
Contingent value rights33,930  
Total liabilities
58,115 8,619 
Commitments and contingencies (Note 7)
Convertible preferred shares (£0.0001 nominal value): No shares authorized issued and outstanding at June 30, 2021; 6,549,205 shares issued and outstanding at December 31, 2020
 25,521 
Combined deficit and shareholders’ equity:
Combined deficit— (22,423)
Series A convertible preferred shares: £0.002 nominal value: 22,840,902 shares authorized. No shares issued and outstanding
 — 
Ordinary shares: £0.002 nominal value: 89,899,419 shares authorized, issued and outstanding at June 30, 2021; No shares authorized, issued and outstanding at December 31, 2020
252 — 
Additional paid-in capital866,889 — 
Accumulated other comprehensive income (loss)3,225 — 
Accumulated deficit(284,724)— 
Total combined deficit and shareholders' equity
585,642 3,098 
Total liabilities, convertible preferred shares, combined deficit and shareholders' equity
$643,757 $11,717 
The accompanying notes are an integral part of these unaudited interim consolidated and combined financial statements.
6

Table of Contents
Centessa Pharmaceuticals plc (Successor) and Centessa Predecessor Group (Predecessor)
Consolidated and Combined Statements of Operations and Comprehensive Loss
(unaudited)
(amounts in thousands except share and per share data)
SuccessorPredecessor
Three months
ended June 30,
2021
Period from
January 30, 2021
through June 30,
2021
Period from
January 1, 2021
through
January 29,
2021
Three months
ended June 30,
2020
Six months ended
June 30, 2020
Operating expenses:
Research and development18,134 28,276 600 1,871 4,681 
General and administrative11,841 17,436 121 258 638 
Change in fair value of contingent value rights11,312 11,312    
Acquired in-process research and development 220,454    
Loss from operations(41,287)(277,478)(721)(2,129)(5,319)
Interest income (expense), net27 35 (9)(17)(34)
Amortization of debt discount  (37)(72)(142)
Other income (expense), net(191)(2,699) (10)(12)
Gain on extinguishment of debt    267 
Net loss(41,451)(280,142)(767)(2,228)(5,240)
Other comprehensive loss:
Foreign currency translation adjustment1,094 3,315 45 (25)(731)
Total comprehensive loss$(40,357)$(276,827)$(722)$(2,253)$(5,971)
Net loss per ordinary share - basic and diluted$(0.65)$(4.89)
Weighted average ordinary shares outstanding - basic and diluted63,516,656 57,309,693 
The accompanying notes are an integral part of these unaudited interim consolidated and combined financial statements.
7

Table of Contents
Centessa Pharmaceuticals plc
Consolidated and Combined Statement of Shareholders' Deficit
(unaudited)
(amounts in thousands except share data)
Series A PreferredOrdinary SharesAdditional
paid-in
capital
Accumulated
Other
Comprehensive
Loss
Accumulated
Deficit
Total
SharesAmountSharesAmount
Balance at January 1, 2021  7,500,000 21  $(86)$(3,149)$(3,214)
Foreign currency translation adjustments— — — — — (4)— (4)
Net loss— — — — — — (1,433)(1,433)
Balance at January 29, 2021 $ 7,500,000 $21 $ $(90)$(4,582)$(4,651)
The accompanying notes are an integral part of these unaudited interim consolidated and combined financial statements.
8

Table of Contents
Centessa Pharmaceuticals plc (Successor)
Consolidated and Combined Statement of Shareholders' Equity
(unaudited)
(amounts in thousands except share data)
Series A PreferredOrdinary SharesAdditional
paid-in
capital
Accumulated
Other
Comprehensive
Loss
Accumulated
Deficit
Total
SharesAmountSharesAmount
Balance at January 30, 2021 $ 7,500,000 $21 $ $(90)$(4,582)$(4,651)
Sale of Series A convertible preferred shares, net of issuance costs of $3,403
22,272,721 241,597 — — — — — 241,597 
Issuance of Series A convertible preferred shares upon conversion of debt568,181 6,250 — — — — — 6,250 
Acquisition of Centessa Subsidiaries— — 44,758,079 123 262,575 — — 262,698 
Forgiveness of convertible term loan— — — — 6,199 — — 6,199 
Repurchase of ordinary shares concurrent with acquisition of Centessa Subsidiaries— — (4,450,000)(12)— — — (12)
Stock option exercises— — 50,000 — 292 — — 292 
Vesting of ordinary shares— — 225,438 1 (1)— —  
Share-based compensation expense— — — — 2,731 — — 2,731 
Foreign currency translation adjustments— — — — — 2,221 — 2,221 
Net loss— — — — — — (238,691)(238,691)
Balance at March 31, 202122,840,902 247,847 48,083,517 133 271,796 2,131 (243,273)278,634 
Conversion of Series A convertible preferred shares into ordinary shares(22,840,902)(247,847)22,840,902 65 247,782 — —  
Sale of ordinary shares in connection with initial public offering, net of issuance costs of $8.8 million
16,500,000 47 298,030 — — 298,077 
Sale of ordinary shares in connection with underwriters exercise of option to purchase in full following initial public offering2,475,000 7 46,052 — — 46,059 
Share-based compensation expense3,229 — — 3,229 
Foreign currency translation adjustments1,094 — 1,094 
Net loss(41,451)(41,451)
Balance at June 30, 2021 $ 89,899,419 $252 $866,889 $3,225 $(284,724)$585,642 
The accompanying notes are an integral part of these unaudited interim consolidated and combined financial statements.
9

Table of Contents
Centessa Predecessor Group (Predecessor)
Combined Statement of Convertible Preferred Shares and Combined Deficit
(unaudited)
(amounts in thousands except share data)
Convertible Preferred SharesCombined
Deficit
Series ASeries BSeries Seed
SharesAmountSharesAmountSharesAmount
Balance at January 1, 20214,337,282 $13,329 1,111,923 $10,840 1,100,000 $1,352 $(22,423)
Foreign currency translation adjustments— — — — — — 45 
Net loss— — — — — — (767)
Balance at January 29, 20214,337,282 $13,329 1,111,923 $10,840 1,100,000 $1,352 $(23,145)



Centessa Predecessor Group (Predecessor)
Combined Statement of Convertible Preferred Shares and Combined Deficit
(unaudited)
(amounts in thousands except share data)
Convertible Preferred SharesCombined
Deficit
Series ASeries BSeries Seed
SharesAmountSharesAmountSharesAmount
Balance at January 1, 20204,337,282 $13,329 1,111,923 $10,840 1,100,000 $1,352 $(11,857)
Share-based compensation expense— — — — — — 63 
Foreign currency translation adjustments— — — — — — (707)
Net loss— — — — — — (3,011)
Balance at March 31, 20204,337,282 13,329 1,111,923 10,840 1,100,000 1,352 (15,512)
Share-based compensation expense— — — — — — 153 
Foreign currency translation adjustments— — — — — — (25)
Net loss— — — — — — (2,228)
Balance at June 30, 20204,337,282 $13,329 1,111,923 $10,840 1,100,000 $1,352 $(17,612)

The accompanying notes are an integral part of these unaudited interim consolidated and combined financial statements.
10

Table of Contents
Centessa Pharmaceuticals plc (Successor) and Centessa Predecessor Group (Predecessor)
Consolidated and Combined Statements of Cash Flows
(unaudited)
(amounts in thousands)
SuccessorPredecessor
Period from
January 30, 2021
through June 30,
2021
Period from
January 1, 2021
through January
29, 2021
 Six months
ended June 30,
2020
Cash flows from operating activities: 
Net loss$(280,142)$(767)(5,240)
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development220,454
Share-based compensation expense5,960153
Depreciation and amortization9
Non-cash interest934
Amortization of debt discount(37)142
Gain on extinguishment of debt(267)
Change in fair value of contingent consideration11,312
Changes in operating assets and liabilities:
Tax incentive receivable(5,187)74(701)
Prepaid expenses and other assets(4,783)681828
Accounts payable2,159(358)(433)
Accrued expenses and other liabilities4,706(589)30
Net cash used in operating activities(45,512)(987)(5,454)
 
Cash flows from investing activities:
Cash acquired upon acquisition of Centessa Subsidiaries68,038
Cash paid to acquire in-process research and development(4,596)
Purchase of property and equipment(74)
Net cash provided by investing activities63,368
Cash flows from financing activities:
Proceeds from the sale of Series A convertible preferred shares, net of issuance costs241,597
Proceeds from the sale of ordinary shares in connection with initial public offering, net of issuance costs paid in cash345,833
Repurchase of ordinary shares(12)
Proceeds from option exercises292
Net cash provided by financing activities587,710
Effect of exchange rate on cash and cash equivalents3,22818(921)
Net increase (decrease) in cash and cash equivalents608,794(969)(6,375)
Cash and cash equivalents at beginning of period4,9657,22716,570
Cash and cash equivalents at end of period$613,759$6,25810,195
Supplemental disclosure of non-cash investing and financing activities:
Issuance of ordinary shares upon acquisition of Centessa Subsidiaries$262,698$
Issuance of contingent value rights upon acquisition of Centessa Subsidiaries$22,618
Issuance of Series A convertible preferred shares upon conversion of debt$6,250$
Forgiveness of convertible term loan$6,199$
Repurchase of ordinary shares concurrent with acquisition of Centessa Subsidiaries$(12)$
Unpaid initial public offering issuance costs at June 30, 2021$1,697$
The accompanying notes are an integral part of these unaudited interim consolidated and combined financial statements.
11

Table of Contents
Centessa Pharmaceuticals plc (Successor) and Centessa Predecessor Group (Predecessor)
Notes to the Unaudited Interim Consolidated and Combined Financial Statements
1. Organization and Description of Business
Centessa Pharmaceuticals plc (“Centessa” or “the Company”) is a pharmaceutical company conceived to develop and deliver life-altering and life-enhancing medicines to patients with an asset-centric research and development logic applied at scale. Centessa was incorporated on October 26, 2020 as a limited liability company under the laws of England and Wales.
In January 2021, the management and equity holders of ApcinteX Limited, Capella Biosciences Limited, Inexia Limited, Janpix Limited, LockBody Therapeutics Ltd, Morphogen-IX Limited, Orexia Limited, Palladio Biosciences, Inc., PearlRiver Bio GmbH, Pega-One S.A.S., and Z Factor Limited (together, the “Centessa Subsidiaries”), contributed the Centessa Subsidiaries to Centessa, in a share for share exchange, after which these companies became wholly-owned subsidiaries of Centessa.
As the Company had no significant operations prior to the contribution of the Centessa Subsidiaries, and the registrant was required to present two years of historical financial statements in its prospectus filed with the SEC on June 2, 2021, the Company’s management (“Management”) sought to identify a predecessor, for which it could include audited historical financial statements, to satisfy the filing requirement. As such, Management sought to identify the predecessor from the population of portfolio companies, which would represent a sizable portion of the historical results of the entities later contributed to Centessa.
Entities affiliated with Medicxi manage multiple investment funds, including – Medicxi Ventures I LP, Medicxi Growth I LP, and Medicxi Secondary I LP. In addition, entities affiliated with Medicxi act as sub advisors to Index Ventures Life VI (Jersey) Limited which advises the managing general partner of Index Ventures Life VI (Jersey), L.P. (all funds collectively are referred to as the “Funds”). Management determined the companies owned by Index Ventures Life VI (Jersey), LP individually represent some of the earliest investments by the Funds. These companies (together, the “Centessa Predecessor Group” or the “Group”) are:
Z Factor Limited (“Z Factor”)
LockBody Therapeutics Ltd (“LockBody”)
Morphogen-IX Limited (“Morphogen-IX”)
As the above entities that comprise the Centessa Predecessor Group were historically under the common control of Index Ventures Life VI (Jersey), LP, the financial statements of the Group are being presented on a combined basis and are denoted as “Predecessor” within these unaudited interim financial statements.

Subsequent to the contribution of the Centessa Subsidiaries to Centessa, the financial activities of Centessa and all Centessa Subsidiaries are being presented on a consolidated basis and are denoted as “Successor” within these unaudited interim financial statements.
Initial Public Offering

In June 2021, the Company completed an initial public offering (“IPO”) of its ordinary shares through the sale and issuance of 16,500,000 American Depository Shares, or ADSs, at an initial price of $20.00 per ADS.     Each ADS represents one ordinary share with a nominal value of £0.002 per ordinary share. Following the close of the IPO, the underwriters fully exercised their option to purchase an additional 2,475,000 ADSs at the initial public offering price of $20.00 per ADS. The Company received aggregate net proceeds of $344.1 million in connection with the IPO and subsequent exercise of the underwriter’s options after deducting underwriting discounts, commissions and other offering expenses paid or to be paid.

Risks and Liquidity

The Group and the Company are subject to risks common to other life science companies in various stages of development including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability, protection of proprietary technology, ability to raise additional financing and compliance with government regulations, in the markets in which the Company is seeking approvals, including U.S. Food and Drug
12

Table of Contents
Centessa Pharmaceuticals plc (Successor) and Centessa Predecessor Group (Predecessor)
Notes to the Unaudited Interim Consolidated and Combined Financial Statements
Administration (“FDA”) regulations. If the Company does not successfully advance its programs, including the Centessa Subsidiaries’ programs, into and through human clinical trials and/or enter into collaborations for its programs and commercialize any of its product candidates, it may be unable to produce product revenue or achieve profitability. For more information on risks, please see Part II Item 1A of this Form10-Q – Risk Factors.

The Group and the Company have incurred losses and negative cash flows from operations since inception and the Company had an accumulated deficit of $(284.7) million as of June 30, 2021. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of the product candidates currently in development by the Centessa Subsidiaries. Substantial additional capital will be needed by the Company to fund its operations (including those of the Centessa Subsidiaries) and to develop its product candidates.

Based on the current non-risk-adjusted operating plan, the Company expects the cash and cash equivalents as of June 30, 2021 of $613.8 million to fund its operations until the end of 2023.
Global Pandemic – COVID-19
On March 10, 2020, the World Health Organization characterized the novel COVID-19 virus as a global pandemic. The Company is continuing to proactively monitor the COVID-19 global pandemic, to assess the potential impact on the business, and to seek to avoid any unnecessary potential delays to the Company’s programs. As of June 30, 2021, the clinical programs and research activities remain largely on track, with some modest delays in clinical trial enrollment rates and supply chain activities. While we are unable to fully quantify the potential effects of this pandemic on our future operations, including potential delays to our pre-clinical and clinical programs, management continues to evaluate and to seek to mitigate risks. The safety and well-being of employees, patients and partners remains our highest priority.
2. Summary of Significant Accounting Policies
References to the unaudited interim combined financial statements of the Centessa Predecessor Group refer to three of the eleven Centessa Subsidiaries that were deemed to represent the predecessor entity prior to the Company’s acquisition of the Centessa Subsidiaries in January 2021. The Centessa Predecessor Group includes the combined financial information of Z Factor, Morphogen-IX and LockBody. The successor includes the consolidated financial information of Centessa and all Centessa Subsidiaries subsequent to the acquisition.

Accordingly, the accompanying unaudited interim consolidated and combined financial statements are presented in accordance with Securities and Exchange Commission (“SEC”) requirements for predecessor and successor financial statements, which include the financial results of both the Company and the Centessa Predecessor Group. The results of operations contained in the unaudited interim consolidated and combined financial statements include the Centessa Predecessor Group’s combined financial results for the three and six months ended June 30, 2020, and the period from January 1, 2021 through January 29, 2021 and the Company’s consolidated financial results for the three months ended June 30, 2021 and for period from January 30, 2021 through June 30, 2021. The unaudited interim consolidated and combined balance sheets present the combined financial position of the Centessa Predecessor Group as of December 31, 2020 and the consolidated financial position of the Company on June 30, 2021.

The accompanying unaudited interim consolidated and combined financial statements should be read in conjunction with the annual audited combined financial statements of the Centessa Predecessor Group (Predecessor) and related notes as of and for the year ended December 31, 2020 and accompanying audited financial statements of Centessa Pharmaceuticals Limited and related notes as of December 31, 2020 found in the prospectus filed with the SEC on June 2, 2021. The Summary of Significant Accounting Policies included in the Company’s annual financial statements and the Centessa Predecessor Group’s annual combined financial statements that can be found in the prospectus, have not materially changed, except as set forth below.

Basis of Presentation and Combination / Consolidation
The accompanying unaudited interim consolidated and combined financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASUs”) promulgated by the Financial Accounting Standards Board (“FASB”).

13

Table of Contents
Centessa Pharmaceuticals plc (Successor) and Centessa Predecessor Group (Predecessor)
Notes to the Unaudited Interim Consolidated and Combined Financial Statements
In the opinion of management, the accompanying unaudited interim consolidated and combined financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly:

the Company’s financial position as of June 30, 2021 and the Predecessor’s financial position as of December 31, 2020;

the Company’s results of operations for the three months ended June 30, 2021 and the period from January 30, 2021 through June 30, 2021, and cash flows for the period from January 30, 2021 through June 30, 2021; and

the Predecessor’s results of operations for the period from January 1, 2021 through January 29, 2021 and for the three and six month periods ended June 30, 2020 and cash flows for the period from January 1, 2021 through January 29, 2021 and six months ended June 30, 2020.

Operating results for the Company from the period from January 30, 2021 through June 30, 2021 are not necessarily indicative of the results that may be expected for the period from January 30, 2021 through December 31, 2021, or for any future period. The unaudited interim consolidated and combined financial statements, presented herein, do not contain all of the required disclosures under U.S. GAAP for annual financial statements. Therefore, these unaudited interim consolidated and combined financial statements should be read in conjunction with the annual audited combined financial statements and related notes for Centessa Pharmaceuticals Limited and Centessa Predecessor Group found in the prospectus filed with the SEC on June 2, 2021.

The Company’s unaudited interim consolidated financial statements include the accounts of Centessa Pharmaceuticals plc, its wholly-owned subsidiary, Centessa Pharmaceuticals, Inc. and the wholly-owned Centessa Subsidiaries. The Centessa Predecessor Group’s unaudited interim combined financial statements included the accounts of Z Factor, Morphogen-IX and LockBody. All intercompany accounts and transactions have been eliminated in consolidation and combination.
Segments

Operating segments are defined as components of an enterprise with separate discrete information available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Centessa Pharmaceuticals plc (Successor) and the Centessa Predecessor Group (Predecessor) view its operations and manage its business as one segment.

Reclassifications

Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on previously reported net loss or comprehensive loss.

Foreign Currency Translation

The Company’s financial statements are presented in U.S. dollars (USD), the reporting currency of the Company. The functional currency of the Centessa Pharmaceuticals plc is USD and the functional currency of the Centessa Subsidiaries is their respective local currency. Income and expenses have been translated into USD at average exchange rates prevailing during the period. Assets and liabilities have been translated at the rates of exchange on the balance sheets dates and equity accounts at their respective historical rates. The resulting translation gain and loss adjustments are recorded directly as a separate component of shareholders’ equity as other comprehensive income (loss). Transactions denominated in a currency other than the functional currency are remeasured based upon the exchange rate at the date of remeasurement with the resulting gain or loss included in the accompanying unaudited interim consolidated and combined statements of operations and comprehensive loss within Other income (expense), net.

Since its formation in October 2020, the functional currency of Centessa Pharmaceuticals plc had been British pounds (GBP), as Centessa Pharmaceutical plc’s primary activities were formation, related transaction costs, primarily denominated in GBP, the acquisition of Centessa subsidiaries predominantly with operations in GBP and the issuance of shares (with a GBP nominal value) as consideration in the acquisition.
14

Table of Contents
Centessa Pharmaceuticals plc (Successor) and Centessa Predecessor Group (Predecessor)
Notes to the Unaudited Interim Consolidated and Combined Financial Statements

Beginning in the second quarter of 2021, the functional currency of Centessa Pharmaceuticals plc, changed from GBP to USD. The change in functional currency is the result of many factors including the completion of an IPO and receipt of proceeds in USD which resulted in USD denominated assets exceeding GBP denominated assets, the increase in its U.S. based employees, and the increase in costs denominated in USD, following completion of the Company’s IPO on a U.S. stock exchange (Nasdaq). Given these significant changes, the Company considered the economic factors outlined in ASC 830, Foreign Currency Matters and concluded that the majority of the factors supported the use of the USD as the functional currency for Centessa Pharmaceutical plc.

The change in functional currency for Centessa Pharmaceuticals plc is applied on a prospective basis beginning as of the second quarter of 2021 and translation adjustments for prior periods will continue to remain as a component of accumulated other comprehensive loss. The Company reclassified the presentation of foreign currency gains and losses recognized first quarter of 2021 from General & administration expense to Other income (expense), net to conform to the current period financial statement presentation.
Use of Estimates
The preparation of unaudited interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited interim consolidated and combined financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited interim consolidated and combined financial statements in the period they are determined to be necessary. Significant areas that require management’s estimates include share-based compensation assumptions, derivative liability and contingent value rights assumptions, accrued research and development expenses, and, prior to the IPO, the fair value of the Company’s ordinary shares.
Property and Equipment, net
Property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of three years. The costs of maintenance and repairs are expensed as incurred. Improvements and betterment that add new functionality or extend the useful life of the asset are capitalized. As of June 30, 2021, the Company had $74,800 of property and equipment, net and primarily comprised of computer equipment. Depreciation expense was $5,434 and $6,807 for the three months ended June 30, 2021 and for the period from January 30, 2021 through June 30, 2021, respectively.
Long-Lived Assets

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, then an impairment charge is recognized for the amount by which the carrying value of the asset exceeds the estimated fair value of the asset. As of June 30, 2021, the Company believes that no revision of the remaining useful lives or write-down of long-lived assets is required.

Contingent Value Rights

The fair value of the contingent value rights liability represents the estimated future payments that will be settled by issuing a variable number of shares and that are contingent upon the achievement of a specified development milestone for Palladio Biosciences, Inc.’s product candidate. The fair value of the contingent value rights is based on the cumulative probability of achieving the specified milestone which is currently expected during the first quarter of 2022. The fair value measurement is based on significant Level 3 unobservable inputs such as the probability of achieving the milestone, anticipated timelines, and discount rate. Changes in the fair value of the liability are recognized in the consolidated statement of operations and comprehensive loss until it is settled.

15

Table of Contents
Centessa Pharmaceuticals plc (Successor) and Centessa Predecessor Group (Predecessor)
Notes to the Unaudited Interim Consolidated and Combined Financial Statements
Acquired In-Process Research and Development Expenses

Acquired in-process research and development (“IPR&D”), consists of the initial up-front payments incurred in connection with the acquisition or licensing of products or technologies in transactions that do not meet the definition of a business under FASB ASC Topic 805, Business Combinations.
Share-Based Compensation

The Company and the Predecessor measure share-based awards at their grant-date fair value and record compensation expense on a straight-line basis over the vesting period of the awards.

Estimating the fair value of share-based awards requires the input of subjective assumptions, including the estimated fair value of the Company and the Predecessor’s ordinary shares, and, for stock options, the expected life of the options and share price volatility. The Company and the Predecessor account for forfeitures of stock option awards as they occur. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in estimating the fair value of share-based awards represent management’s estimate and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.

The expected life of the stock options is estimated using the “simplified method,” as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option. For share price volatility, the Company uses comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected life of the option.

Awards granted for ordinary shares of Centessa Pharmaceuticals plc (Successor) are accounted for as restricted share-based awards. The estimated fair value of the restricted shares is based upon the estimated fair value of Centessa Pharmaceutical plc’s (Successor) ordinary shares at grant date.
Net Loss Per Ordinary Share

Basic loss per ordinary share is computed by dividing net loss by the aggregate weighted-average number of ordinary shares outstanding. Diluted loss per ordinary share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred shares, stock options, unvested restricted ordinary shares and convertible debt which would result in the issuance of incremental ordinary shares. For diluted net loss per ordinary share, the weighted-average number of ordinary shares is the same for basic net loss per ordinary share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average ordinary shares outstanding for the three months ended June 30, 2021 and for the period from January 30, 2021 through June 30, 2021, as they would be anti-dilutive.

Unvested ordinary shares988,342 
Stock options10,530,410 
11,518,752 



16

Table of Contents
Centessa Pharmaceuticals plc (Successor) and Centessa Predecessor Group (Predecessor)
Notes to the Unaudited Interim Consolidated and Combined Financial Statements
Recently Issued Accounting Pronouncements

In October 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2020-10-Codification Improvements. For public business entities, the amendments in this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The amendments in this update do not change U.S. GAAP and, therefore, are not expected to result in a significant change in practice. Section A was removed from the final update of ASU 2020-10. Section B of this update contains amendments that improve the consistency of the Codification by including all disclosure guidance in the appropriate Disclosure Section (Section 50). Section C of this update contains Codification improvements that vary in nature. The Company adopted ASU 2020-10 on January 30, 2021 and it did not have a material impact to the Company’s unaudited interim consolidated and combined financial statements and related disclosures.

In August 2020, the FASB issued ASU 2020-06, “(Subtopic 470-20): Debt—Debt with Conversion and Other Options” (“ASU 2020-06”) to address the complexity associated with applying GAAP to certain financial instruments with characteristics of liabilities and equity. ASU 2020-06 includes amendments to the guidance on convertible instruments and the derivative scope exception for contracts in an entity’s own equity and simplifies the accounting for convertible instruments which include beneficial conversion features or cash conversion features by removing certain separation models in Subtopic 470-20. Additionally, ASU 2020-06 will require entities to use the “if-converted” method when calculating diluted earnings per share for convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023 (fiscal year 2024 for the Group), including interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2020-06 to the unaudited interim consolidated and combined financial statements and related disclosures.

In March 2020, the FASB issued ASU 2020-03, “Codification Improvements to Financial Instruments”: The amendments in this update are to clarify, correct errors in, or make minor improvements to a variety of ASC topics. The changes in ASU 2020-03 are not expected to have a significant effect on current accounting practices. The ASU improves various financial instrument topics in the Codification to increase stakeholder awareness of the amendments and to expedite the improvement process by making the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. The ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022 with early application permitted. The Company is currently evaluating the impact the adoption of this guidance may have on its unaudited interim consolidated and combined financial statements.

In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,” which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. The Company is currently evaluating ASU 2019-12 and its impact on the unaudited interim consolidated and combined financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases, which requires a lessee to record a right-of-use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. A modified retrospective transition approach is required for lessees for finance and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. As the Company has elected to use the extended transition period for complying with new or revised accounting standards as available under the Jobs Act, the standard is effective for the Company beginning January 1, 2022, with early adoption permitted. The Company is currently evaluating the impact of adoption to the unaudited interim consolidated and combined financial statements and related disclosures.

3. Acquisition of Centessa Subsidiaries
In January 2021, the Company entered into a merger agreement with the Centessa Subsidiaries whereby the Company acquired 100% of the outstanding Centessa Subsidiaries’ shares in exchange for, in aggregate, 44,758,079 ordinary shares of the Company. In addition, the Company issued certain contingent value rights to the selling shareholders of Palladio Biosciences, Inc.
As part of the acquisition, the Company issued replacement equity awards to select employees and consultants of certain Centessa Subsidiaries. The awards consisted of options and restricted shares with vesting provisions generally consistent with the original awards prior to the acquisition. The Company determined that a portion of the fair value of the replacement awards should be a component of consideration paid to acquire the Centessa Subsidiaries, with the remaining value of the award accounted for as post-combination share-based compensation expense.
17

Table of Contents
Centessa Pharmaceuticals plc (Successor) and Centessa Predecessor Group (Predecessor)
Notes to the Unaudited Interim Consolidated and Combined Financial Statements
The acquisition of each Centessa Subsidiary has been treated as a separate asset acquisition as the Company determined that none of the Centessa Subsidiaries meet the definition of a business due to substantially all of the fair value of each entity being concentrated in a single asset or group of assets which represent the IPR&D or the entity did not have the requisite inputs and substantive processes to be considered a business. The Company’s acquired IPR&D expense of $223.6 million, of which $3.1 million was in connection with transaction costs recognized prior to January 30, 2021, and reflects the fair value of consideration ascribed to the product candidates in each subsidiary, as the Company determined the assets had no alternative future use.
The total purchase price for the asset acquisitions was calculated as follows (amounts in thousands):
Estimated fair value of Centessa ordinary shares issued$261,387 
Estimated fair value of replacement equity awards allocated to consideration paid1,310 
Estimated fair value of contingent value rights22,618 
Transaction costs4,597 
Total consideration given$289,912 
The following table summarizes the assets acquired and liabilities assumed as of the acquisition date for the asset acquisitions (in thousands):
Assets acquired:
Cash and cash equivalents$68,038 
Tax incentive receivable8,752 
Prepaid expenses and other current assets2,551 
Other assets203 
In-process research and development assets223,593 
Total assets acquired303,137 
Liabilities assumed:
Accounts payable3,607 
Accrued expenses and other current liabilities3,128 
Convertible notes6,199 
Loan with related party291 
Total liabilities assumed13,225 
Net assets acquired$289,912 
The Company’s determinations of the fair value of the ordinary shares were performed using methodologies, approaches and assumptions in accordance with the guidance outlined in the American Institute of Certified Public Accountants’ Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, (“Practice Guide”). In accordance with the Practice Guide, the Centessa Successor considered the following methods for allocating the enterprise value across its classes and series of capital shares to determine the fair value of its ordinary shares at each valuation date.
Option Pricing Method (“OPM”). The OPM estimates the value of the ordinary equity of the Company using the various inputs in the Black-Scholes option pricing model. The OPM treats the rights of the holders of ordinary shares as equivalent to that of call options on any value of the enterprise above certain break points of value based upon the liquidation preferences of the holders of the Company’s convertible preferred shares, as well as their rights to participation, and the share prices of the outstanding options. Thus, the value of the ordinary shares can be determined by estimating the value of its portion of each of these call option rights. Under this method, the ordinary shares have value only if the funds available for distribution to shareholders exceed the value of the liquidation preference at the time of a liquidity event, such as a merger or sale. Given the ordinary shares represents a non-marketable equity
18

Table of Contents
Centessa Pharmaceuticals plc (Successor) and Centessa Predecessor Group (Predecessor)
Notes to the Unaudited Interim Consolidated and Combined Financial Statements
interest in a private enterprise, an adjustment to the preliminary value estimates had to be made to account for the lack of liquidity that a shareholder experiences. This adjustment is commonly referred to as a discount for lack of marketability (“DLOM”).
Probability-Weighted Expected Return Method (“PWERM”). The PWERM is a scenario-based analysis that estimates the value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes considered by the Company, as well as the economic and control rights of each share class.
Hybrid Method. The Hybrid Method is a hybrid between the PWERM and OPM, estimating the probability-weighted value across multiple scenarios, but using the OPM to estimate the allocation of value within one or more of those scenarios. Weighting allocations are assigned to the OPM and PWERM methods factoring possible future liquidity events.
The Company estimated the fair value of its ordinary shares based on the Hybrid Method. Subjective factors considered by the Company’s board of directors and management included the pending addition of new executive members and the election of new independent directors to the Company’s board of directors, as well as definitive plans to undertake an IPO. There are significant judgments and estimates inherent in the determination of the fair value of ordinary shares. These judgments and estimates include assumptions regarding the Company’s future operating performance, the time to complete an initial public offering or other liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, its ordinary shares could have been significantly different.
At the time of the acquisitions, all outstanding unvested share-based awards of the Centessa Predecessor Group vested immediately. The unrecognized compensation expense of $4.1 million was recognized at the time of the acquisitions.
In connection with the acquisition of the Centessa Subsidiaries, the Company issued contingent value rights (CVR), to former shareholders and option holders of Palladio. The CVR represent the contractual rights to receive payment of $39.7 million upon the first patient dosed in a Phase 3 pivotal study of lixivaptan for the treatment of autosomal dominant polycystic kidney disease (“ADPKD”) in any of the United States, France, Germany, Italy, Spain, the United Kingdom and Japan (designated the ACTION Study). The contingent CVR milestone, if triggered, will be settled through the issuance of the Company’s ordinary shares equal to the amount of the total CVR payable based on the per share value of ordinary shares at the milestone date.

The Company determined that the CVR should be accounted for as a liability in accordance with ASC 480. Accordingly, the fair value of the contingent consideration is assessed quarterly until settlement. To estimate the fair value of the contingent consideration, the Company applied a cumulative probability of achieving the clinical milestone and applied it to the potential payout. While the Company will consider the status and on-going results of the Phase 3a safety study (designated the ALERT Study), an open-label study for which enrollment is on-going, the Company intends to commence the Phase 3 pivotal study (designated the ACTION study) in parallel with the ALERT Study. Therefore, the probability of commencing the ACTION study and dosing the first patient is high and the milestone is currently expected in the first quarter of 2022. The cumulative probability of dosing the first patient in the ACTION Study was applied to the CVR payout to arrive at a fair value of $22.6 million as of the acquisition date of the Centessa Subsidiaries. The change in fair value from the date of acquisition to June 30, 2021 of $11.3 million is reflected in the consolidated and combined statement of operations and comprehensive loss, and results in a fair value of the CVR liability as of June 30, 2021 of $33.9 million.
4. Fair Value Measurement
Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments be made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company’s financial instruments, including prepaid expense and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. The Company follows the provisions of FASB ASC Topic 820, Fair Value Measurement, for financial assets and liabilities measured on a
19

Table of Contents
Centessa Pharmaceuticals plc (Successor) and Centessa Predecessor Group (Predecessor)
Notes to the Unaudited Interim Consolidated and Combined Financial Statements
recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:
Level 1:    Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
Level 2:    Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.
Level 3:    Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
The following fair value hierarchy table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis (in thousands):
Fair value measurement at reporting date using
Quoted prices
in active markets for
identical assets
(Level 1)
Significant
other
observable inputs (Level 2)
Significant
unobservable inputs
(Level 3)
June 30, 2021 (Successor)
Liabilities
Contingent Value Rights$ $ $33,930 
Fair value measurement at reporting date using
Quoted prices
in active markets for
identical assets
(Level 1)
Significant
other
observable inputs (Level 2)
Significant
unobservable inputs
(Level 3)
December 31, 2020 (Predecessor)
Liabilities
Derivative liability$ $ $913 

The Centessa Predecessor Group evaluated a redemption feature within the convertible term notes and determined bifurcation of the redemption feature was required. The redemption feature is classified as a liability on the accompanying consolidated and combined balance sheet at December 31, 2020. The liability is marked-to-market each reporting period with the changes in fair value recorded in the unaudited interim consolidated and combined statements of operations and comprehensive loss until it is settled. The derivative liability was considered a Level 3 liability because its fair value measurement was based, in part, on significant inputs not observed in the market. The fair value of the derivative was estimated primarily on the probability of the next fund raising occurring and the timing of such event. Upon completion of the acquisition of the Centessa Subsidiaries in January 2021, the derivative liability was settled and is no longer subject to remeasurement.
The acquisition-date fair value of the contingent valuation rights liability represents the future payments that are contingent upon the achievement of a specified development milestone for Palladio’s product candidate. The fair value of the contingent value rights is based on the cumulative probability of achieving the specified milestone which is currently expected during the first quarter of 2022. The fair value measurement is based on significant Level 3 unobservable inputs such as the probability of achieving the milestone, anticipated timelines, and discount rate. Changes in the fair value of the liability will be recognized in the unaudited interim consolidated and combined statement of operations and comprehensive loss until it is settled.
20

Table of Contents
Centessa Pharmaceuticals plc (Successor) and Centessa Predecessor Group (Predecessor)
Notes to the Unaudited Interim Consolidated and Combined Financial Statements
The reconciliation of the redemption feature measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (amounts in thousands):
Contingent Value RightsDerivative Liability
Balance at January 1, 2021 (Predecessor)
$— $913 
Additions—  
Change in fair value—  
Settlements— (913)
Balance at January 29, 2021 (Predecessor)
$— $ 
Balance at January 30, 2021 (Successor)
$ $— 
Additions22,618 — 
Balance at March 31, 2021 (Successor)
22,618 — 
Change in fair value of contingent value rights11,312 — 
Balance at June 30, 2021 (Successor)
$33,930 $— 
5. Balance Sheet and Combined Deficit Components
Prepaid expenses and other current assets consist of the following (in thousands):
SuccessorPredecessor
June 30,
2021
December 31,
2020
D&O Insurance$10,234 $9 
Research and development costs3,941 992 
Value added tax receivable1,365 298 
Other444 6 
$15,984 $1,305 
Accrued expenses and other current liabilities consist of the following (in thousands):
SuccessorPredecessor
June 30,
2021
December 31,
2020
D&O Insurance$8,367 $ 
Research and development expenses3,984 1,001 
Professional fees3,271 37 
Personnel related expenses907  
Other395 9 
$16,924 $1,047 
21

Table of Contents
Centessa Pharmaceuticals plc (Successor) and Centessa Predecessor Group (Predecessor)
Notes to the Unaudited Interim Consolidated and Combined Financial Statements
Combined deficit of the Centessa Predecessor Group at December 31, 2020 consisted of the following (in thousands):
Predecessor
December 31,
2020
Morphogen-IX deficit
Ordinary shares$13 
Additional paid-in capital364 
Accumulated other comprehensive income629 
Accumulated deficit(9,225)
Total Morphogen-IX deficit$(8,219)
Z Factor deficit
Ordinary shares$12 
Additional paid-in capital461 
Accumulated other comprehensive income139 
Accumulated deficit(8,568)
Total Z Factor deficit$(7,956)
LockBody deficit
Ordinary shares$ 
Additional paid-in capital 
Accumulated other comprehensive income (loss)(196)
Accumulated deficit(6,052)
Total LockBody deficit$(6,248)
Total combined deficit$(22,423)
6. Debt
Centessa Pharmaceuticals Limited Convertible Term Notes
In December 2020, the Company entered into a convertible loan agreement (the Agreement) with Medicxi Growth, whereby the Company issued $5.0 million of unsecured convertible term notes to Medicxi Growth. The convertible loans were issued as a bridge financing in contemplation of completing the Series A financing within the next six months. The convertible term notes had a stated interest rate of 8% per annum, which was not payable until settlement of the principal, being the maturity date June 29, 2021. Upon completion of the Company’s Series A preferred financing in January 2021, the Company issued 568,181 shares of its Series A convertible preferred shares and settled all outstanding principal and unpaid interest associated with the convertible term notes.
LockBody Therapeutics Ltd Convertible Term Notes

In July 2019, LockBody entered into a convertible term note agreement to issue up to £5.0 million of convertible term notes of which £3.0 million was received in July 2019 and an additional £1.0 million was received in November 2020.
The convertible term notes had a stated interest rate of 2% per annum, which was not payable until settlement of the principal, being the maturity date of August 2, 2021.
The principal and accrued interest due under the convertible term notes converts:
into the class of LockBody’s shares issued in LockBody’s next qualified fund raising, at a conversion price after applying a 20% discount to the purchase price per share paid for the shares.
on a change of control, at a conversion price after applying a 50% discount to the purchase price per share paid for the shares.
22

Table of Contents
Centessa Pharmaceuticals plc (Successor) and Centessa Predecessor Group (Predecessor)
Notes to the Unaudited Interim Consolidated and Combined Financial Statements
As a result of the fact that the convertible term notes were convertible into a variable number of preferred shares, the Centessa Predecessor Group evaluated the conversion provision as a redemption feature. The redemption feature was evaluated as an embedded derivative and bifurcated from the convertible term notes due to the substantial premium paid upon redemption and accounted for as a derivative instrument. Upon bifurcating the redemption feature, the Group recorded aggregate debt discounts of $0.7 million that is recognized in interest expense over the term of the convertible term notes. The notes and the derivative liability were assumed in connection with the acquisition of the Centessa Subsidiaries in January 2021 and immediately forgiven. The forgiveness was recognized as $6.2 million contribution within the Successor consolidated statement of shareholders’ equity during the period from January 30, 2021 through June 30, 2021.

7. Commitments and Contingencies
Commitments
As of June 30, 2021, the Company had non-cancellable commitments for purchase of clinical materials, contract manufacturing, maintenance, and committed funding of up to $18.9 million, of which the Company expects to pay $15.8 million within one year and the remaining $3.1 million over one to three years. The amount and timing of these payments vary depending on the rate of progress of development. Future clinical trial expenses have not been included within the purchase commitments because they are contingent on enrollment in clinical trials and the activities required to be performed by the clinical sites.
Contingencies
From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Group accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated.
Litigation
The Company, to its knowledge, is not a party to any litigation as of June 30, 2021, that, if determined adversely, would have a material adverse effect on its business and operations.
8. Convertible Preferred Shares
As of December 31, 2020, the Centessa Predecessor Group had Series A, Series B and Seed Series convertible preferred shares outstanding that were subject to redemption under certain “deemed liquidation” events, as defined in each of the Centessa Predecessor Group entities’ articles of association. The Series A, Series B and Seed Series convertible preferred shares are classified outside of combined deficit as the deemed liquidation events are outside of the each of the Centessa Predecessor Group entities’ control. Upon consummation of the acquisition of the Centessa Subsidiaries, all outstanding convertible preferred shares of the Centessa Predecessor Group were converted into ordinary shares of the Centessa Predecessor Group and ultimately exchange for ordinary shares of Centessa Pharmaceuticals Limited at the time of acquisition. Immediately following the acquisition, the Centessa Subsidiaries became wholly-owned subsidiaries of the Centessa Pharmaceuticals Limited whereby no convertible preferred shares were issued and outstanding at the Centessa Subsidiaries level.
Ordinary Shares
Ordinary shares confer upon its holders voting rights, the right to receive cash and stock dividends, if declared, and the right to share in excess assets upon liquidation of the Company. The holders of ordinary shares are entitled to one vote per share. In January 2021, the Company issued 45,137,984 ordinary shares in connection with the acquisition of the Centessa Subsidiaries of which 379,905 shares were replacement share-based awards and subject to future vesting requirements. Concurrent with the acquisition, the Company repurchased 4,450,000 of its A ordinary shares from several of its founders for a nominal amount.
Series A Convertible Preferred Shares
In January 2021, the Company sold 22,272,721 shares of its Series A convertible preferred shares at a purchase price of $11.00 per share in exchange for gross proceeds of $245.0 million. Upon completion of the Series A preferred financing, the Company
23

Table of Contents
Centessa Pharmaceuticals plc (Successor) and Centessa Predecessor Group (Predecessor)
Notes to the Unaudited Interim Consolidated and Combined Financial Statements
issued 568,181 Series A convertible preferred shares upon settling the outstanding principal, unpaid interest, and bifurcated derivative liability associated with its convertible term notes.
Dividends
The holders of Preferred Shares are entitled to dividends if and when declared by the Company’s board of directors. As of June 30, 2021, no dividends have been declared and no Preferred Shares are outstanding.
Voting
Each preferred share is entitled to a vote on an as-converted basis and certain significant Group events require majority approval from the preferred shareholders as a separate class.
Conversion
Each preferred share is convertible, at the holder’s option, into such number of ordinary shares on a one-to-one basis and equal to the conversion price then in effect. The conversion price is subject to adjustments for splits, dividends, distributions and other similar recapitalization events. Upon consummation of a qualified initial public offering of the Company’s securities, the preferred shares would automatically convert into ordinary shares.
Liquidation Preference
Upon the liquidation, sale, or merger of the Company (collectively, the Liquidation), the preferred shareholders are entitled to receive an amount equal to the original issuance price plus any unpaid declared dividends. If there are additional available assets from the liquidation after the initial liquidation payments, the remaining available assets will be distributed to the ordinary shareholders.
9. Share-based Compensation
The Company and the Centessa Predecessor Group recorded share-based compensation expense in the following expense categories in the unaudited interim consolidated and combined statements of operations and comprehensive loss (in thousands):
SuccessorPredecessor
Three Months Ended
June 30, 2021
Period from January 30, 2021 through
June 30, 2021
Period from January 1, 2021 through
January 29, 2021
Three Months Ended
June 30, 2020
Six Months Ended
June 30, 2020
Research and development$924 $2,041 $ $90 $153 
General and administrative2,305 3,919    
$3,229 $5,960 $ $90 $153 
Centessa Pharmaceuticals plc (Successor) Stock Options
In January 2021, the Company’s board of directors approved the 2021 Equity Incentive Plan (the 2021 Plan). The number of shares authorized under the 2021 Plan was increased in May 2021 at the time of the IPO, whereby the total number of shares authorized under the 2021 Plan was 19,192,910 of which 8,662,500 shares were available for future grants as of June 30, 2021. The Plan provides for the granting of ordinary shares, incentive stock options, non-qualified stock options, restricted share awards, and/or share appreciation rights to employees, directors, and other persons, as determined by the Company’s board of directors. The Company’s stock options vest based on the terms in each award agreement, generally over four-year periods, and have a contractual term of ten years.
24

Table of Contents
Centessa Pharmaceuticals plc (Successor) and Centessa Predecessor Group (Predecessor)
Notes to the Unaudited Interim Consolidated and Combined Financial Statements
The following table summarizes stock option activity for the period from January 30, 2021 through June 30, 2021:
Number of SharesWeighted-Average Exercise Price Per ShareWeighted-Average Remaining Contractual Term
Balance at January 30, 2021 
Granted11,414,307 $6.89 
Exercised(50,000)$5.84 
Forfeited(833,897)$5.84 
Balance at June 30, 2021
10,530,410 $6.98 9.6
Exercisable at June 30, 2021
518,857 $4.40 7.6
The weighted-average grant date fair value of options granted was $6.98 per share for the period from January 30, 2021 through June 30, 2021. As of June 30, 2021, the total unrecognized compensation expense related to unvested stock option awards was $41.8 million, which the Company expects to recognize over a weighted-average period of 2.4 years.
Based on the trading price of $21.22 per ADS, which is the closing price as of June 30, 2021, the aggregate intrinsic value of options as of June 30, 2021 was $160.4 million, of which $9.2 million is related to vested options.
During the period from January 30, 2021 through June 30, 2021, the fair value of each option was estimated on the date of grant using the weighted average assumptions in the table below:
Expected term (in years)5.84
Expected stock price volatility65.51 %
Risk-free interest rate0.85 %
Expected dividend yield0 %
Estimated fair value of ordinary share$6.98
Restricted Share Awards
In connection with the acquisition of the Centessa Subsidiaries, the Company issued 379,905 ordinary shares subject to future vesting. In the three months ended June 30, 2021, the Company issued 833,897 ordinary shares subject to future vesting to an employee. The fair value of the awards are based upon the estimated fair value of the Company’s ordinary shares at the time of grant.
The following table summarizes ordinary share activity for the period from January 30, 2021 through June 30, 2021:
Number of SharesWeighted-Average Grant Date Fair Value Per Share
Unvested at January 30, 2021 
Granted1,213,802 $15.57 
Vested(225,460)$5.84 
Unvested at June 30, 2021
988,342 $17.79 
As of June 30, 2021, the total unrecognized compensation expense related to unvested ordinary shares was $16.7 million, which the Company expects to recognize over a weighted-average period of 2.5 years.

25

Table of Contents
Centessa Pharmaceuticals plc (Successor) and Centessa Predecessor Group (Predecessor)
Notes to the Unaudited Interim Consolidated and Combined Financial Statements
10. Licensing Arrangements
In connection with the acquisition of the Centessa Subsidiaries, the Company acquired the following licensing arrangements:
Z Factor Limited License Agreement
In 2015 and subsequently amended in 2017, Z Factor entered into an exclusive worldwide license agreement to further develop and commercialize, small molecule chaperones to correct the folding of Z-A1AT for the treatment of kidney and lung disease. The Group is solely responsible for, and is required to use commercially reasonable efforts to, research, develop, manufacture and commercialize the licensed technology, at its own costs. The Group is also responsible for supplying all active pharmaceutical ingredients and finished drug product for exploitation. The Group is obligated to make up to $0.5 million (£0.4 million at an exchange rate of 0.73) in payments upon the achievement of development and regulatory milestones. In addition, the Group is obligated to fund any patent related costs associated with the licensed technology. No expenses were incurred during the three months ended June 30, 2021 and 2020, the period from January 1, 2021 through January 29, 2021 and the period from January 30, 2021 through June 30, 2021 in connection with the license agreement.
Morphogen-IX  Limited License Agreement
In 2015, Morphogen-IX entered into an exclusive worldwide license agreement to further develop and commercialize, the licensed technology for PAH. The Company is responsible for supplying all active pharmaceutical ingredients and finished drug product for exploitation. The Company is obligated to make up to $1.0 million (£0.8 million at an exchange rate of 0.73) in payments upon the achievement of development and regulatory milestones. The Company is also obligated to make future commercial milestone payments at low to mid-single digit royalty rates for net product sales and is subject to adjustment in the event the Group sublicenses the approved technology. In addition, the Company is obligated to pay an annual licensing fee and obligated to fund any patent related costs associated with the licensed technology. No expenses were incurred during the three months ended June 30, 2021 and 2020, the period from January 1, 2021 through January 29, 2021 and the period from January 30, 2021 through June 30, 2021 in connection with the license agreement.
Palladio Biosciences Inc. Lixivaptan License Agreement
Palladio entered into an exclusive worldwide license agreement to further develop and commercialize Lixivaptan, a nonpeptide selective vasopressin V2 receptor antagonist for the treatment of ADPKD. In relation to the purchase of the license, the Company is obligated to make certain contingent consideration payments to the seller in the event a Licensed Product is commercialized. Such payments are structured as a tiered percentage of net sales and capped at $32.5 million. The Company is obligated to make up to $16.3 million in commercial milestone payments. In addition, the Company is obligated to make future royalty payments (the first $19.0 million of which would be due to Pfizer) at low to mid single digit royalty rates for net product sales and is subject to adjustment in the event the Company sublicenses the approved technology. The Company incurred no expense during the period from January 30, 2021 through June 30, 2021 in connection with the license agreement.
ApcinteX Limited SerpinPC License Agreement
ApcinteX entered into an exclusive, sublicensable, worldwide license agreement with Cambridge Enterprise Limited (“CE”), to further develop and commercialize the patented technology held by CE for modified serpins for the treatment of bleeding disorders through the use of rational and random mutagenesis associated with the patented technology. The Company is solely responsible for, and is required to use commercially reasonable efforts to, research, develop, manufacture and commercialize the patented technology, at its own costs. The Company is obligated to make up to $1.0 million (£0.7 million at an exchange rate of 0.73) in development and regulatory milestone payments and low single digit royalty rates for net product sales. The Company incurred no expense during the period from January 30, 2021 through June 30, 2021 in connection with the license agreement.
Pega-One S.A.S. License Agreement with Hoffman-La Roche
Pega-One entered into, and subsequently amended, a license agreement with Hoffman La Roche Ltd, or Roche, to discover, develop and commercialize GA201 which is a glycoengineered anti-EGFR monoclonal antibody imgatuzumab for the treatment of cutaneous squamous cell carcinoma and other solid tumor indications. The Company retains an exclusive worldwide sublicensable royalty bearing license. Pega-One made an upfront payment of $2.0 million and is obligated to pay up to $16.0
26

Table of Contents
Centessa Pharmaceuticals plc (Successor) and Centessa Predecessor Group (Predecessor)
Notes to the Unaudited Interim Consolidated and Combined Financial Statements
million upon the achievement of development and regulatory milestones and up to $125.0 million in commercial milestones subject to potential increase if Pega-One undergoes a change in control transaction before a specified event for a specific indication. Pega-One is also obligated to pay Roche tiered royalties on net sales of the licensed product at rates ranging from a mid to high single percentage, on a country-by-country and product-by-product basis and is subject to adjustments in the event the Company sublicenses the approved technology. In addition, Pega-One is obligated to reimburse Roche for annual patent related costs incurred related to the license. Upon consummation of a strategic transaction or an initial public offering of the Pega-One’s ordinary shares, as defined in the license agreement, Roche is entitled to receive a minimum of 10% of the consideration received by the Company. Such consideration was received in connection with the acquisition of the Centessa Subsidiaries in January 2021.
Janpix Limited License Agreement
Janpix entered into an exclusive worldwide license agreement to further develop and commercialize the licensed compounds. Janpix is obligated to make up to $30.0 million in development and commercial milestone payments. In addition, Janpix is obligated to make future commercial milestone payments at low to mid-single digit royalty rates for net product sales.
Capella Biosciences Limited License Agreement
Capella entered into a license agreement with Lonza Sales AG to further evaluate, develop and commercialize licensed compounds for therapeutic use. Capella is obligated to make additional payments contingent upon approval to advance through additional stages of the process. Capella is obligated to make up to $